Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $213.475 million which beat the analyst consensus estimate of $203.764 million by 4.77 percent. This is a 3.75K percent increase over sales of $5.546 million the same period last year.